Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009—Results from a Randomized First-in-Human Phase 1 Trial

BACKGROUND: Complement may play a key role in antibody-mediated rejection. A promising therapeutic approach may be classical pathway (CP) inhibition at the level of early component C1. METHODS: In this first-in-human, double-blind, randomized placebo-controlled phase 1 trial, we evaluated the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühlbacher, Jakob, Jilma, Bernd, Wahrmann, Markus, Bartko, Johann, Eskandary, Farsad, Schörgenhofer, Christian, Schwameis, Michael, Parry, Graham C., Gilbert, James C., Panicker, Sandip, Böhmig, Georg A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Clinical Science—General
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610566/
https://www.ncbi.nlm.nih.gov/pubmed/28926521
http://dx.doi.org/10.1097/TP.0000000000001804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610566/
https://www.ncbi.nlm.nih.gov/pubmed/28926521
http://dx.doi.org/10.1097/TP.0000000000001804

Ejemplares similares